Want to see IN:ERIS full AI Analyst Report?
ERIS Stock Chart & Stats
₹1398.90
₹2.90(0.21%)
At close: 4:00 PM EDT
₹1398.90
₹2.90(0.21%)
Day’s Range― - ―
52-Week Range₹1,237.90 - ₹1,805.20
Previous CloseN/A
Volume38.23K
Average Volume (3M)2.07K
Market Cap
₹181.77B
Enterprise Value₹202.70K
Total Cash (Recent Filing)₹673.00M
Total Debt (Recent Filing)₹23.59B
Price to Earnings (P/E)28.0
Beta0.63
Next Earnings
Oct 23, 2026EPS Estimate
11.3Next Dividend Ex-DateN/A
Dividend Yield0.55%
Share Statistics
EPS (TTM)45.40
Shares Outstanding138,583,300
10 Day Avg. Volume1,915
30 Day Avg. Volume2,071
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)4.54
Price to Sales (P/S)5.67
P/FCF Ratio354.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)47.06
Revenue Forecast (FY)₹35.42B
Bulls Say, Bears Say
Bulls Say
Strong Operating ProfitabilityHigh gross and operating margins indicate strong brand economics and pricing power in Eris’s prescription portfolio. Sustained profitability provides internal funding capacity and resilience against operating cost pressure.
Improved LeverageDeleveraging has strengthened the balance sheet and reduced financial risk compared with FY2024. Although debt remains meaningful, the improvement increases flexibility to support product investment and absorb business volatility.
Chronic Therapy PortfolioConcentration in chronic therapies supports recurring prescription demand because patients often require long-term treatment. This creates a durable base for brand retention, doctor relationships and continued portfolio expansion in India.
Bears Say
Weak Cash ConversionThe sharp decline in operating and free cash flow indicates that accounting earnings are not converting reliably into cash. Persistent working-capital or investment demands could constrain reinvestment, debt reduction and shareholder returns.
Debt Above Historical BaselineDespite recent deleveraging, the company carries substantially more leverage than in its earlier history. This raises fixed financial obligations and makes cash-flow weakness more consequential if growth or profitability softens.
Earnings And Growth VolatilityModerate revenue growth and changing gross and net margins suggest that earnings quality depends partly on product mix and operating conditions. This may limit the predictability of future profit expansion despite healthy current margins.
Eris Lifesciences Ltd News
ERIS FAQ
What was Eris Lifesciences Ltd’s price range in the past 12 months?
Eris Lifesciences Ltd lowest stock price was ₹1237.90 and its highest was ₹1805.20 in the past 12 months.
What is Eris Lifesciences Ltd’s market cap?
Eris Lifesciences Ltd’s market cap is ₹181.77B.
When is Eris Lifesciences Ltd’s upcoming earnings report date?
Eris Lifesciences Ltd’s upcoming earnings report date is Oct 23, 2026 which is in 54 days.
How were Eris Lifesciences Ltd’s earnings last quarter?
Eris Lifesciences Ltd released its earnings results on Jul 29, 2026. The company reported ₹10.3 earnings per share for the quarter, missing the consensus estimate of ₹10.767 by -₹0.467.
Is Eris Lifesciences Ltd overvalued?
According to Wall Street analysts Eris Lifesciences Ltd’s price is currently Overvalued.
Does Eris Lifesciences Ltd pay dividends?
Eris Lifesciences Ltd pays a Notavailable dividend of ₹7.21 which represents an annual dividend yield of 0.55%. See more information on Eris Lifesciences Ltd dividends here
What is Eris Lifesciences Ltd’s EPS estimate?
Eris Lifesciences Ltd’s EPS estimate is 11.3.
How many shares outstanding does Eris Lifesciences Ltd have?
Eris Lifesciences Ltd has 138,583,300 shares outstanding.
What happened to Eris Lifesciences Ltd’s price movement after its last earnings report?
Eris Lifesciences Ltd reported an EPS of ₹10.3 in its last earnings report, missing expectations of ₹10.767. Following the earnings report the stock price went up 2.573%.
Which hedge fund is a major shareholder of Eris Lifesciences Ltd?
Currently, no hedge funds are holding shares in IN:ERIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eris Lifesciences Ltd
Eris Lifesciences Limited is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of medicinal products throughout the country. The company provides a comprehensive range of branded formulations, catering to a wide spectrum of therapeutic areas. These encompass cardiovascular health, anti-diabetic treatments, anti-infectives, antipyretics, vitamin/nutrient supplements, gastroenterology, respiratory care, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, alongside services in in-vitro fertilization, cosmetology, and dermatology. Founded in 2007, Eris Lifesciences Limited is headquartered in Ahmedabad, India.
Technical Analysis
Alkem Laboratories Ltd.
―
Alembic Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
Mankind Pharma Ltd.
―
Torrent Pharmaceuticals Ltd
―